{"id":"NCT00727597","sponsor":"Georgetown University","briefTitle":"A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT","officialTitle":"A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-07","primaryCompletion":"2010-08","completion":"2011-07","firstPosted":"2008-08-04","resultsPosted":"2013-07-02","lastUpdate":"2013-07-02"},"enrollment":101,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Human Immunodeficiency Virus Infections"],"interventions":[{"type":"DRUG","name":"Efavirenz 600mg","otherNames":["Efavirenz(Sustiva)600 mg"]},{"type":"DRUG","name":"Boosted Lexiva","otherNames":["Fosamprenavir(Lexiva)"]}],"arms":[{"label":"Arm A : Boosted Lexiva plus Epzicom","type":"EXPERIMENTAL"},{"label":"Arm B: Efavirenz plus Epzicom","type":"EXPERIMENTAL"}],"summary":"The hope of this study is to gather data and information about the tolerability and effectiveness of Lexiva versus Sustiva in patients who have have been generally underrepresented in clinical trials.","primaryOutcome":{"measure":"Number of Subjects Needing to Switch Comparator Drugs (FPV/r or EFV)","timeFrame":"96 weeks","effectByArm":[{"arm":"Once Daily (QD) Regimen of Lexiva","deltaMin":1,"sd":null},{"arm":"QD Regimen of Sustiva","deltaMin":2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["23741991"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":51},"commonTop":["cholesterol, total neutrophils, creatine kinase, and triglycerides"]}}